Director Of Bioinformatics, Correlative Sciences
Worked with clinical operations, translational medicine, and biostatics groups on the TRIDENT-1 trial (repotrectinib), which is a tyrosine kinase inhibitor for the treatment of patients with locally advanced or metastatic ROS1 fusion positive non-small cell lung cancer. Reviewed biomarkers (fusions and oncogenic activating mutations) for patient trial eligibility for TRIDENT-1, as well as several other trials.Worked with external partners to develop clinical trial assays. Identified biomarkers from solid tumor and liquid biopsy (on target/off target) correlated with subject drug response and clinical efficacy of Repotrectinib. Developed integrated biospecimen shipping, tracking and testing systems.